Should biologics for psoriasis be interrupted in the era of COVID-19?

J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
No abstract available

Publication types

  • Letter

MeSH terms

  • Betacoronavirus
  • Biological Products / administration & dosage*
  • Biological Products / therapeutic use
  • COVID-19
  • Coronavirus Infections / complications*
  • Humans
  • Nasopharyngitis / complications
  • Pandemics
  • Pneumonia, Viral / complications*
  • Psoriasis / complications
  • Psoriasis / drug therapy*
  • Respiratory Tract Infections / complications
  • Risk Factors
  • SARS-CoV-2
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Biological Products
  • Tumor Necrosis Factor-alpha